tbuckley/cabot-search huggingface dataset:
Enhanced cholera surveillance to improve vaccination campaign efficiency
Authors: Hanmeng Xu, Kaiyue Zou, Juan Dent, Kirsten E. Wiens, Espoir Bwenge Malembaka, Godfrey Bwire, Placide Welo Okitayemba, Lee M. Hampton, Andrew S. Azman, Elizabeth C. Lee
Journal: Nature Medicine (2024)

Systematic testing for Vibrio cholerae O1 is rare, which means that the world's limited supply of oral cholera vaccines (OCVs) may not be delivered to areas with the highest true cholera burden. Here we used a phenomenological model with subnational geographic targeting and fine-scale vaccine effects to model how expanding V. cholerae testing affected impact and cost-effectiveness for preventive vaccination campaigns across different bacteriological confirmation and vaccine targeting assumptions in 35 African countries. Systematic testing followed by OCV targeting based on confirmed cholera yielded higher efficiency and cost-effectiveness and slightly fewer averted cases than status quo scenarios targeting suspected cholera. Targeting vaccine to populations with an annual incidence rate greater than 10 per 10,000, the testing scenario averted 10.8 (95% prediction interval (PI) 9.4-12.6) cases per 1,000 fully vaccinated persons while the status quo scenario averted 6.9 (95% PI 6.0-7.8) cases per 1,000 fully vaccinated persons. In the testing scenario, testing costs increased by US$31 (95% PI 25-39) while vaccination costs reduced by US$248 (95% PI 176-326) per averted case compared to the status quo. Introduction of systematic testing into cholera surveillance could improve efficiency and reach of global OCV supply for preventive vaccination.
Characterization of Vascular Niche in Systemic Sclerosis by Spatial Proteomics
Authors: Aleix Rius Rigau, Yi-Nan Li, Alexandru-Emil Matei, Andrea-Hermina Györfi, Peter-Martin Bruch, Sarah Koziel, Veda Devakumar, Armando Gabrielli, Alexander Kreuter, Jiucun Wang, Sascha Dietrich, Georg Schett, Jörg H.W. Distler, Minrui Liang
Journal: Circulation Research (2024)

Systemic sclerosis (SSc) is a connective tissue disease that can serve as a model to study vascular changes in response to inflammation, autoimmunity, and fibrotic remodeling. Although microvascular changes are the earliest histopathologic manifestation of SSc, the vascular pathophysiology remains poorly understood.
Peptide targeting improves the delivery and therapeutic index of glucocorticoids to treat rheumatoid arthritis
Authors: Xian Wu, Hong Guo, Hui Gao, Yiqin Li, Xiangxiang Hu, Mitchell A. Kowalke, Yue-Xuan Li, Yushuang Wei, Jiaqi Zhao, Jennifer Auger, Bryce A. Binstadt, Hong-Bo Pang
Journal: Journal of Controlled Release (2024)
Adult-Onset Still’s Disease (AOSD): Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options
Authors: Sara Bindoli, Chiara Baggio, Andrea Doria, Paolo Sfriso
Journal: Drugs (2024)

Adult-onset Still's disease (AOSD) is a multisystemic complex disorder clinically characterised by episodes of spiking fever, evanescent rash, polyarthritis or diffuse arthralgias; multiorgan involvement may develop according to the hyper-inflammatory extent. The pathogenesis of AOSD is not completely recognised. The central role of macrophage activation, which results in T helper 1 (Th1) cell cytokine activation, is well established. Pro-inflammatory cytokines such as interleukin (IL)-1, IL-6 and IL-18 play a fundamental role in disease onset and progression. The disease may develop in both children and adults with overlapping clinical features, and although several subsets depending on the clinical manifestations and the cytokines expressed have been identified, the dichotomy between systemic juvenile idiopathic arthritis (sJIA) and AOSD nowadays has been overcome, and the pathology is considered a disease continuum between ages. Various therapeutic approaches have been evaluated thus far, and different compounds are under assessment for AOSD treatment. Historically, glucocorticoids have been employed for treating systemic manifestations of Still's disease, while conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) demonstrated efficacy in controlling the articular manifestations. Currently, biological (b) DMARDs are widely employed; IL-1 inhibitors such as anakinra and canakinumab have proven to have high efficacy and an excellent safety profile and the anti-IL-6 tocilizumab is approved for sJIA, with several trials and longitudinal studies confirming its efficacy and safety. Moreover, in the light of the 'window of opportunity', new evidence showed that the earlier these treatments are initiated, the sooner clinical inactivity can be achieved. Other treatment options are being considered since several molecules involved in the disease pathophysiology can be targeted through various mechanisms. This review will provide a broad overview of AOSD pathophysiology, insights into specific organ manifestations and the currently available treatments with the identification of potential therapeutic targets involved in AOSD pathogenesis will be outlined.
Effect of long‐term tafamidis treatment on health‐related quality of life in patients with transthyretin amyloid cardiomyopathy
Authors: Martha Grogan, Margot K. Davis, Maria G. Crespo‐Leiro, Marla B. Sultan, Balarama Gundapaneni, Franca Stedile Angeli, Mazen Hanna
Journal: European Journal of Heart Failure (2024)

To evaluate the effect of long-term tafamidis treatment on health-related quality of life (HRQoL) in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) enrolled in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension (LTE) study.
Association of diabetes‐specific heart failure risk score with presence of subclinical cardiomyopathy among individuals with diabetes: A prospective study
Authors: Zainali S. Chunawala, Neil Keshvani, Matthew W. Segar, Kershaw V. Patel, Muhammad Shariq Usman, Vinayak Subramanian, Viraj Raygor, Alvin Chandra, Muhammad Shahzeb Khan, Ambarish Pandey
Journal: European Journal of Heart Failure (2024)
A metagenomic prospective cohort study on gut microbiome composition and clinical infection in small bowel transplantation
Authors: Archana Madhav, Rachel Bousfield, Joana Pereira-Dias, Claire Cormie, Sally Forrest, Jacqueline Keane, Leanne Kermack, Ellen Higginson, Gordon Dougan, Harry Spiers, Dunecan Massey, Lisa Sharkey, Charlotte Rutter, Jeremy Woodward, Neil Russell, Irum Amin, Andrew Butler, Kayleigh Atkinson, Tom Dymond, Josefin Bartholdson Scott, Stephen Baker, Effrossyni Gkrania-Klotsas
Journal: Gut Microbes (2024)

Two-thirds of small-bowel transplantation (SBT) recipients develop bacteremia, with the majority of infections occurring within 3 months post-transplant. Sepsis-related mortality occurs in 31% of patients and is commonly caused by bacteria of gut origin, which are thought to translocate across the implanted organ. Serial post-transplant surveillance endoscopies provide an opportunity to study whether the composition of the ileal and colonic microbiota can predict the emergence as well as the pathogen of subsequent clinical infections in the SBT patient population. Five participants serially underwent aspiration of ileal and colonic bowel effluents at transplantation and during follow-up endoscopy either until death or for up to 3 months post-SBT. We performed whole-metagenome sequencing (WMS) of 40 bowel effluent samples and compared the results with clinical infection episodes. Microbiome composition was concordant between participants and timepoint-matched ileal and colonic samples. Four out of five (4/5) participants had clinically significant infections thought to be of gut origin. Bacterial translocation from the gut was observed in 3/5 patients with bacterial infectious etiologies. In all three cases, the pathogens had demonstrably colonized the gut between 1–10 days prior to invasive clinical infection. Recipients with better outcomes received donor grafts with higher alpha diversity. There was an increase in the number of antimicrobial resistance genes associated with longer hospital stay for all participants. This metagenomic study provides preliminary evidence to support the pathogen translocation hypothesis of gut-origin sepsis in the SBT cohort. Ileal and colonic microbiome compositions were concordant; therefore, fecal metagenomic analysis could be a useful surveillance tool for impeding infection with specific gut-residing pathogens.
The urine DNA methylation assay facilitates whole course management of urothelial carcinoma in a large multicentric, prospective China cohort
Authors: X. Chen, Z. Liu, L. Zhou, J. Fan, Q. Lv, Q. Wei, H. Chen, T. Xu, W. Tan, L. Li, S. Wang, A. Xu, J. Yang, H. Liao, J. Fan, J. Huang, T. Lin
Journal: European Urology (2024)
<i>Bifidobacterium</i> alleviate metabolic disorders via converting methionine to 5’-methylthioadenosine
Authors: Qiang Lyu, Rou-An Chen, Hsiao-Li Chuang, Hsin-Bai Zou, Lihong Liu, Li-Kang Sung, Po-Yu Liu, Hsin-Yi Wu, Hsin-Yuan Chang, Wan-Ju Cheng, Wei-Kai Wu, Ming-Shiang Wu, Cheng-Chih Hsu
Journal: Gut Microbes (2024)

Dietary patterns and corresponding gut microbiota profiles are associated with various health conditions. A diet rich in polyphenols, primarily plant-based, has been shown to promote the growth of probiotic bacteria in the gastrointestinal tract, subsequently reducing the risk of metabolic disorders in the host. The beneficial effects of these bacteria are largely due to the specific metabolites they produce, such as short-chain fatty acids and membrane proteins. In this study, we employed a metabolomics-guided bioactive metabolite identification platform that included bioactivity testing using in vitro and in vivo assays to discover a bioactive metabolite produced from probiotic bacteria. Through this approach, we identified 5'-methylthioadenosine (MTA) as a probiotic bacterial-derived metabolite with anti-obesity properties. Furthermore, our findings indicate that MTA administration has several regulatory impacts on liver functions, including modulating fatty acid synthesis and glucose metabolism. The present study elucidates the intricate interplay between dietary habits, gut microbiota, and their resultant metabolites.
Multi-institutional European outcomes of supervised unexperienced resident in transurethral resection of bladder cancer: The importance of a standardized program, the ENTRY project working group
Authors: P. Diana, M. Paciotti, A. Gallioli, E. Vercelli, D. D’Agate, M.L. Piccinelli, E. Lievore, F. Dagnino, A. Finocchiaro, A. Yebes Alonso, N. Frego, A. Bravo, P. Hernandez, L. Martinez Pineiro, O. De Cobelli, P. Gontero, J. Palou, A. Mottrie, A. Breda, N. Buffi
Journal: European Urology (2024)
Development of a sensetive digital droplet PCR screening assay for the detection of GPR126 non-coding mutations in bladder cancer urine liquid biopsies
Authors: A. Tivtikyan, D. Kamalov, M. Jain, D. Okhobotov, D. Vitaly, L. Samokhodskaya, S. Avdonin, T. Rakhmatullin, M. Zvereva, A. Kamalov
Journal: European Urology (2024)
Prostatic ductal adenocarcinoma and comparison to high-risk acinar adenocarcinoma of the prostate in patients undergoing Robotic Radical Prostatectomy (RARP): A prostate cancer referral centre review
Authors: S.K. Reddy, M. Covas Moschovas, S. Saikali, A. Gamal, M. Sandri, T. Harvey, R. Kenneth, V. Patel
Journal: European Urology (2024)
Assessing the impact and timing of salvage radiation therapy in men with biochemically recurrent prostate cancer after radical prostatectomy and negative PSMA PET
Authors: D. Cannoletta, E. Mazzone, G. Gandaglia, A. Stabile, V. Cucchiara, M. Picchio, C. Cozzarini, A. Chiti, P. Scilipoti, M. Longoni, G. Sorce, F. Pellegrino, G.O. Cirulli, D. Robesti, R. Leni, L. Quarta, A. Necchi, A. Raggi, F. Montorsi, A. Briganti
Journal: European Urology (2024)
Radical prostatectomy for non-metastatic prostate cancer in renal transplant recipients: Outcomes from a large contemporary cohort and matched-paired analysis with non-transplanted patients
Authors: S. Tappero, A. Marquis, F. Barletta, M. Allasia, M. Oderda, C. Dariane, O. Timsit, J. Branchereau, B. Mesnard, D. Tilki, J. Olsburgh, M. Kulkarni, V. Kasivisvanathan, C. Lebacle, A. Breda, A. Galfano, G. Gandaglia, A. Briganti, F. Montorsi, L. Biancone, P. Gontero, G. Marra
Journal: European Urology (2024)
The relationship between mental wellbeing and functional outcomes in the first year of a prostate cancer diagnosis
Authors: O. Brunckhorst, J. Liszka, C. James, J. Fanshawe, M. Hammadeh, R. Thomas, S. Khan, M. Sheriff, H. Ahmed, M. Van Hemelrijck, G. Muir, R. Stewart, P. Dasgupta, K. Ahmed
Journal: European Urology (2024)
Association of area deprivation index and race with prostate cancer-specific mortality among Non-Hispanic black and Non-Hispanic white men in a contemporary North American population.
Authors: G.O. Cirulli, M. Finati, G. Chiarelli, A. Stephens, S. Tinsley, M. Butaney, P. Etta, S. Arora, C. Morrison, G. Lughezzani, N. Buffi, G. Carrieri, A. Salonia, A. Briganti, F. Montorsi, C. Rogers, F. Abdollah
Journal: European Urology (2024)
Radiomics-based prognostic model guided by artificial intelligence to predict lymph node invasion and biochemical recurrence in patients with high-grade prostate cancer
Authors: N. Touma, M. Larose, R. Brodeur, F. Desroches, N. Raymond, D. Bédard-Tremblay, D. Leblanc, F. Rasekh, H. Hovington, B. Neveu, M. Vallières, L. Archambault, F. Pouliot
Journal: European Urology (2024)
Impact of RAS inhibitors on prostate cancer aggressiveness – a retrospective multicenter analysis by the Young academic urologists prostate cancer group
Authors: N. Artamonova, M. Kafka, L. Faiss, D. Avetisyan, I. Puche Sanz, G. La Bombarda, G. Iacono, F. Zattoni, E. Steiner, C. D’Elia, A. Pycha, G. Gandaglia, W. Horninger, I. Heidegger
Journal: European Urology (2024)
Carbohydrate antigen 125 concentrations across the ejection fraction spectrum in chronic heart failure: The <scp>EMPEROR</scp> programme
Authors: João Pedro Ferreira, Milton Packer, Naveed Sattar, Javed Butler, Stuart J. Pocock, Stefan D. Anker, Sandra González Maldonado, Marina Panova‐Noeva, Mikhail Sumin, Serge Masson, Faiez Zannad, James L. Januzzi
Journal: European Journal of Heart Failure (2024)
Validation of a blood-based sphingolipid panel for men with prostate cancer on active surveillance
Authors: J.R. Gregg, E. Irajizad, L. Newcomb, R. Wu, J. Dennison, J.W. Davis, C. Pettaway, L. Pisters, J.F. Ward, B.F. Chapin, L. Chery, A. Urkmez, P. Troncoso, C.R. Daniel, A.W. Hahn, M. Liu, Y. Zheng, D. Lin, S. Hanash, J. Fahrmann
Journal: European Urology (2024)
Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study
Authors: Zimu Gong, Godsfavour Umoru, Jorge Monge, Nishi Shah, Ghulam Rehman Mohyuddin, Sabarinath Venniyil Radhakrishnan, Rajshekhar Chakraborty, Leo Rasche, Carolina Schinke, Anita D’Souza, Meera Mohan
Journal: Blood Cancer Journal (2024)
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
Authors: Meera Mohan, Jorge Monge, Nishi Shah, Danny Luan, Mark Forsberg, Vineel Bhatlapenumarthi, Metodi Balev, Anannya Patwari, Heloise Cheruvalath, Divaya Bhutani, Sharmilan Thanendrarajan, Binod Dhakal, Maurizio Zangari, Samer Al-Hadidi, Dennis Cooper, Suzanne Lentzsch, Frits van Rhee, Anita D’Souza, Aniko Szabo, Carolina Schinke, Rajshekhar Chakraborty
Journal: Blood Cancer Journal (2024)

Abstract The objective of our study was to report real-world data on the safety and efficacy of standard-of-care teclistamab in patients with relapsed/refractory multiple myeloma (MM). This is a multi-institutional retrospective cohort study and included all consecutive patients that received at least one dose of teclistamab up until August 2023. One hundred and ten patients were included, of whom, 86% had triple-class refractory disease, 76% penta-refractory disease, and 35% had prior exposure to B-cell maturation antigen (BCMA)-targeting therapies. The overall response rate (ORR) in our cohort was 62%, with a ≥ very good partial remission (VGPR) rate of 51%. The ORR in patients with and without prior BCMA-targeted therapies was 54% vs 67%, respectively ( p = 0.23). At a median follow-up of 3.5 months (range, 0.39–10.92), the estimated 3 month and 6 month progression free survival (PFS) was 57% (95% CI, 48%, 68%) and 52% (95% CI, 42%, 64%) respectively. The incidence of cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS) was 56% and 11% respectively, with grade ≥3 CRS and ICANS noted in 3.5% and 4.6% of patients respectively. 78 unique infections were diagnosed in 44 patients, with the incidence of all-grade and grade ≥3 infections being 40% vs 26% respectively. Primary prophylaxis with intravenous immunoglobulin (IVIG) was associated with a significantly lower infection risk on multivariate analysis (Hazard ratio [HR] 0.33; 95% CI 0.17, 0.64 ; p = 0.001).
Assessing predictive factors for Disease-Free Survival (DFS) and Overall Survival (OS) in patients eligible for adjuvant immunotherapy (IO) following Radical Cystectomy (RC) for Muscle-Invasive Bladder Cancer (MIBC)
Authors: N. Foschi, C. Ciccarese, P. Russo, F. Marino, F. Rossi, G. Maioriello, A. Anghelone, G.B. Filomena, F. Fantasia, G. Tortora, R. Iacovelli
Journal: European Urology (2024)
Natural history of cN+ bladder cancer treated with radical cystectomy with or without perioperative treatment
Authors: M. von Deimling, M. Furrer, A. Mari, L.S. Mertens, A. Khanna, R. Li, M. Maas, M. Moschini, A. Bianchi, R. Pichler, J. Taylor, C. Lonati, F. Crocetto, K.H. Tully, L. Afferi, F. del Giudice, Y. Lotan, P.C. Black, P.E. Spiess, A. Minervini, B. Kiss, M. Fisch, B. Pradere, S.F. Shariat
Journal: European Urology (2024)
Detection of prostate cancer recurrences with prostate-specific membrane antigen positron emission tomography after curative radiotherapy: A call for reconsideration of the Phoenix criteria
Authors: E. van Altena, B.H.E. Jansen, M. Korbee, W. Luining, P. Leeuwen, M. Wondergem, D. Oprea-Lager, A. Vis
Journal: European Urology (2024)
Impact of neoadjuvant chemo-immunotherapy on intra and post operative outcomes in patients with bladder cancer treated with radical cystectomy and pelvic lymph node dissection: Prospective surgical assessment from the NURE-Combo Trial
Authors: C. Re, F. Pellegrino, M. Longoni, P. Scilipoti, M. De Angelis, G. Avesani, C. Mercinelli, A. Cigliola, D. Patanè, D. Raggi, R. Lucianò, R. Colombo, G. Gandaglia, A. Briganti, F. Montorsi, A. Necchi, M. Moschini
Journal: European Urology (2024)
Complete response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is time for a paradigm shift in surgical treatment?
Authors: R.S. Flammia, G. Tuderti, R. Mastroianni, A. Brassetti, A.M. Bove, F. Proietti, L. Misuraca, S. D’Annunzio, G. Chiacchio, A. Minore, S. Basile, U. Anceschi, M.C. Ferriero, S. Guaglianone, C. Leonardo, G. Simone
Journal: European Urology (2024)
Robust reactive oxygen species modulator hitchhiking yeast microcapsules for colitis alleviation by trilogically intestinal microenvironment renovation
Authors: Jintao Li, Jian Song, Zhichao Deng, Jian Yang, Xiaoqin Wang, Bowen Gao, Yuanyuan Zhu, Mei Yang, Dingpei Long, Xiaoqin Luo, Mingxin Zhang, Mingzhen Zhang, Runqing Li
Journal: Bioactive Materials (2024)

Ulcerative colitis (UC) is characterized by chronic inflammatory processes of the intestinal tract of unknown origin. Current treatments lack understanding on how to effectively alleviate oxidative stress, relieve inflammation, as well as modulate gut microbiota for maintaining intestinal homeostasis synchronously. In this study, a novel drug delivery system based on a metal polyphenol network (MPN) was constructed via metal coordination between epigallocatechin gallate (EGCG) and Fe
Advanced PEG-tyramine biomaterial ink for precision engineering of perfusable and flexible small-diameter vascular constructs via coaxial printing
Authors: Julia Simińska-Stanny, Lise Nicolas, Adam Chafai, Hafez Jafari, Maryam Hajiabbas, Gianina Dodi, Ioannis Gardikiotis, Christine Delporte, Lei Nie, Daria Podstawczyk, Amin Shavandi
Journal: Bioactive Materials (2024)

Vascularization is crucial for providing nutrients and oxygen to cells while removing waste. Despite advances in 3D-bioprinting, the fabrication of structures with void spaces and channels remains challenging. This study presents a novel approach to create robust yet flexible and permeable small (600–1300 μm) artificial vessels in a single processing step using 3D coaxial extrusion printing of a biomaterial ink, based on tyramine-modified polyethylene glycol (PEG-Tyr). We combined the gelatin biocompatibility/activity, robustness of PEG-Tyr and alginate with the shear-thinning properties of methylcellulose (MC) in a new biomaterial ink for the fabrication of bioinspired vessels. Chemical characterization using NMR and FTIR spectroscopy confirmed the successful modification of PEG with Tyr and rheological characterization indicated that the addition of PEG-Tyr decreased the viscosity of the ink. Enzyme-mediated crosslinking of PEG-Tyr allowed the formation of covalent crosslinks within the hydrogel chains, ensuring its stability. PEG-Tyr units improved the mechanical properties of the material, resulting in stretchable and elastic constructs without compromising cell viability and adhesion. The printed vessel structures displayed uniform wall thickness, shape retention, improved elasticity, permeability, and colonization by endothelial-derived - EA.hy926 cells. The chorioallantoic membrane (CAM) and in vivo assays demonstrated the hydrogel's ability to support neoangiogenesis. The hydrogel material with PEG-Tyr modification holds promise for vascular tissue engineering applications, providing a flexible, biocompatible, and functional platform for the fabrication of vascular structures.
A multifunctional biomimetic nanoplatform for image-guideded photothermal-ferroptotic synergistic osteosarcoma therapy
Authors: Yu-jie Liu, Su-he Dong, Wen-hao Hu, Qiao-ling Chen, Shao-fu Zhang, Kai Song, Zhen-chuan Han, Meng-meng Li, Zhi-tao Han, Wei-bo Liu, Xue-song Zhang
Journal: Bioactive Materials (2024)

Much effort has been devoted to improving treatment efficiency for osteosarcoma (OS). However, most current approaches result in poor therapeutic responses, thus indicating the need for the development of other therapeutic options. This study developed a multifunctional nanoparticle, PDA-MOF-E-M, an aggregation of OS targeting, programmed death targeting, and near-infrared (NIR)-aided targeting. At the same time, a multifunctional nanoparticle that utilises Fe-MOFs to create a cellular iron-rich environment and erastin as a ferroptosis inducer while ensuring targeted delivery to OS cells through cell membrane encapsulation is presented. The combination of PDA-MOF-E-M and PTT increased intracellular ROS and LPO levels and induced ferroptosis-related protein expression. A PDA-based PTT combined with erastin showed significant synergistic therapeutic improvement in the anti-tumour efficiency of the nanoparticle in vitro and vivo. The multifunctional nanoparticle efficiently prevents the osteoclasia progression of OS xenograft bone tumors in vivo. Finally, this study provides guidance and a point of reference for clinical approaches to treating OS.